Amazon, Walmart, and OpenAI are the latest companies to take their logos in a bold direction—literally.

Obesity drugmaker Novo Nordisk said on Wednesday it would drop gender representation requirements for its U.S. business ...

GSK's latecomer to the PD-1/PD-L1 inhibitor category Jemperli has barely started to bring in revenues, and is a world away from the company's hopes of blockbuster revenues by 2031.

Eisai has now presented the full results from its phase 3 confirmatory Clarity AD study for early Alzheimer’s disease and published them in the New England Journal of Medicine (NEJM).

The biggest stories of the day delivered to your inbox.